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TNFa/cachectin, produced bymononuclear phagocytes and other cells, is thought
to be a critical mediator of the septic shock syndrome by inducing hypotension, ac-
tivating leukocytes, promoting endothelial coagulant activity, and causing metabolic
acidosisand acute renal failure (1-3). Although endotoxins from Gram-negative bac-
teria are thought to produce septic shock in part by inducing the synthesis and re-
lease ofTNF (3), Gram-positive organisms, fungi, and acute antigen-antibody reac-
tions (such as transfusion reactions) can also produce a shock-like state (4).
Human C5a is an 11-kD glycopeptide generated by the cleavage ofC5 by either
the classical or alternative complement pathway convertases, or by other proteases
(5). An anaphylatoxin, C5a is chemotactic for phagocytec leukocytes ; it stimulates
the generation of LTB4 and oxygen radicals, release of lysosomal enzymes, degran-
ulation ofmast cells, and induces vasodilation and vascular permeability (5-7). C5a
also enhances lymphocyte function (8) .
C5a is generated in the course of sepsis, trauma, and other inflammatory states
(5) associated with the acute phase response. Many of the acute phase responses
are due to the actions of the cytokines, TNFa and IL-1 (9), and both may play im-
portant roles in the septic shock syndrome (10) .
Goodman et al . (11) reported that the murine macrophage line, P388D1, secreted
IL-1 in response to C5a . We have recently reported that human C5a and C5a des
Argstimulated IL-1 release from freshly obtainedhuman mononuclear cells (MNC),
in the absence of endotoxin (12) .
In this study, we comparedhuman mononuclear cell secretionofimmunoreactive
IL-la, IL-1p, andTNFa in response to stimulation by purified human C5a . Our
results indicate that C5a is apotent stimulus of mononuclear cell secretion of these
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cytokines, and does so in a dose-dependent fashion . With increasingC5a concentra-
tions, there was increased secretion ofTNFa, IL-1(3, and IL-la. There was no statisti-
cally significant difference between the amount of TNFa or IL-1/3 secreted in re-
sponse to a given C5a stimulus . Both TNFa and IL-1(i were secreted in significantly
greater concentrations than IL-la in response to C5a stimulation . Our results sug-
gest thatcomplement activation may influence hemodynamic, hematologic, and meta-
bolic functions by the induction of these cytokines .
Materials and Methods
Materials.
￿
C5a and C5a des Arg were isolated by immunoadsorbent column chromatog-
raphy, ion exchange, and gel filtration, as previously described (13) . Endotoxin was not de-
tected in C5a by the Limulus Amoebocyte Lysate (LAL) assay (sensitivity of 20 pg/ml ; As-
sociates of Cape Cod, Woods Hole, MA) . A positive control was used in which 20 pg/ml
of Escherichia coli endotoxin (Sigma ChemicalCo., St . Louis, MO) was mixed withC5a (250
ng/ml) .
HumanMNC Incubations .
￿
Human MNC were isolated from heparinized (5 U/ml) venous
blood from four healthy donors as previously described (12) . MNC were suspended at 5 x
10 6 cells/ml in Eagle'sMEM (Gibco, Grand Island, NY) . To examine the effect ofC5a on
cytokine production, 100 Wl of various concentrations of the purified C5a diluted in MEM
were incubated with 100 ul ofMNC suspension in 96-well flat bottomed microtiter wells and
then incubated for 24 h in serum-free conditions at 37°C . Because stimulatedMNC produce
PGE2 in response to C5a, indomethacin (final concentration, 0.5 wg/ml) was added to the
media to inhibit cyclooxygenase (12) . Although the endotoxin levels of theC5a samples were
undetectable (<20 pg/Wg C5a), endotoxin might be capable ofstimulating IL-1 orTNF produc-
tion at levels below the sensitivity ofthe LAL test (14). PolymyxinB has been shown to block
many ofthe in vitro effects ofendotoxins present in a wide variety ofbiologically active sub-
stances . Therefore, each sample of C5a was preincubated with 5 wg/ml ofpolymyxin B (PMB,
clinical grade ; Pfizer Inc., New York, NY) for 1 h at room temperature in the absence of serum .
Reports from other laboratories and our previous studies demonstrate that PMB neutralizes
the ability of exogenously added LPS to induce cytokine production ; PMB had no effect on
C5a-induced IL-1 production (12). This further confirmed the absence of significant endotoxin
contamination of these C5a preparations .
The effect ofhumanC5a onMNC TNFa and IL-1 production was examined over a broad
range of concentrations, from 1-500 ng/ml . After 24 h ofincubation at 37°C, the superna-
tants of theMNC were diluted and assayed for TNFa and IL-1a and IL-10 levels by using
the respective RIAs .
RIAs .
￿
3 RIAs were used to measure TNFa (15), IL-10 (16), and IL-1a (17) . TheseRIAs
have been shown to detect <100 pg/ml ofeach cytokine in humanMNC supernatants . Detailed
studies, described elsewhere (15-17), demonstrate that there is no crossreactivity amongst
each of these cytokine RIAs, nor do these RIAs detect human IFN-a, IFN -7, granulocyte-
macrophage CSF, lymphotoxin, or C5a. In addition, each RIA correlated with functional
bioassays (cytotoxicity, T cell proliferation), with correlation coefficients of >0.8 (p < 0.05
by paired student's t test) . Bioassay for TNFa used the L929 cytotoxicity assay, as described
in our report detailing the RIA method for TNFa (15) .
Results
Comparison ofHuman MNC Production of TNF-a, IL-1P, and IL-la in Response to
C5a. A dose-dependent effect ofC5a on TNFa, IL-10, and IL-1a secretion was
clearly observed in theMNC of all donors (Fig. 1) . With increasing concentrations
of C5a, increased cytokine secretion was observed . Due to greater variability for
TNFa production between individuals, IL-10andTNFa levels at varyingC5a con-
centrations did not differ significantly (p > 0 .05 by paired student's t test and anal-OKUSAWA ET AL.
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ysis ofvariance (ANOVAI), while secreted IL-1 0 levels were sign
IL-1a levels over a broad range of C5a concentrations (25-500 ng/ml C5a; p <
0.05-0.01 by paired student's t test and ANOVA). Significant (¢ < 0.05) MNC
cytokine production over control levels required a C5a concentration of 25 ng/ml
for IL-10, 50 ng/ml for TNFa, and 200 ng/ml for IL-1a. We also compared the
response to both C5a and purified C5a des Arg. TNFa and IL-10 secretion in re-
sponse to C5a des Arg was approximately one-tenth to one-fifth that seen for C5a
over a biologically relevant range ofanaphylatoxin concentrations from 30-100 ng/ml
(data not shown). The addition of C5a to 20% normal human serum gave results
intermediate between C5a des Arg and C5a (data not shown).
When the same supernatants were assayed for TNF bioactivity using the L929
cell cytotoxicity bioassay, standardized against human TNFa, similar patterns were
observed. When the data from both the bioassay and RIA were compared, a strong
linear correlation was observed (r = 0.92).
Effect of Polymyxin B Preincubation on C5a-stimulated TNF-a Production.
￿
Endotoxin
in our C5a preparations was undetectable (<20 pg/Itg). The preincubation of C5a
with polymyxin B had no influence on TNFa production by MNC (b > 0.05); when
endotoxin (100 ng/ml) was preincubated with PMB (5 gg/ml), MNC TNF-a produc-
tion was effectively blocked. Identical results were seen when IL-Ia and IL-ID were
assayed.
Discussion
Human C5a has been reported to stimulate IL-1 production in P388DI cells, a
murine macrophage cell line (11), and we have recently shown that purified human
C5a stimulates normal human peripheral blood MNC to produce IL-10 (12). In the
present studies, we report that C5a induces TNFa production in human PBMC,
demonstrated by both RIA and bioassay. In addition, we compared the in vitro secre-
tion ofTNFa with IL-10 and IL-la . C5a increases the production ofthesecytokines
in a dose-dependent fashion, There were no statistically significant differences be-
tween the increases seen for both TNFa and IL-ID in response to clinically achiev-
able concentrations of C5a (ranging from 25-100 ng/ml). Both TNFa and IL-ID
were secreted in significantly greater concentrations in response to C5a than IL-Ia.446
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When purified C5a desArg was compared with C5a, we found that TNFa and IL-
10 secretion in response to C5a des Arg was approximately one tenth to one fifth
as great as that for C5a. Addition of C5a to 20% normal human serum gave results
intermediate between C5a desArgandthe more potent C5a. This is not surprising,
as serumcarboxypeptidase B rapidlyconverts C5a to C5adesArg, reducing itspotency
as a stimulus, while additional serum factors such as C3 cleavage products (C3a,
iC3b) and clotting products maybe stimulatory. It is forthesereasons that we chose,
in these initial investigations, to study purified C5a in serum-free media.
In these studies, the C5a was free of any detectable endotoxin, and potential en-
dotoxin effects were additionally controlled by the inclusion of polymyxin B in ap-
propriate incubations. The effectiveness of PMB in blocking detectable endotoxin
stimulation of cytokine production was documented in our investigation.
Recently, it has been appreciated that polypeptide factors, elaborated by the host
in response to stimuli such as infectionmediate responses such as fever, acute phase
protein synthesis, abnormal metabolism, and shock. Forexample, the C3HIHeJ mouse
is resistant to the effects of LPS, presumably due to genetic defect in the post-
translational production of TNF and IL-1 (18). TNFa and IL-1 are both mediators
ofthe acute phaseresponse; both are capable, administered individually, ofinducing
fever and the shocksyndrome, and share many of the same biological activities (1-3,
10, 19). Together, these cytokines act synergistically to mediate the local Schwartz-
man reaction (20), as well as the shock syndrome (10). Since C5a induces these
cytokinestogether, theirsynergismmaybe relevant in a number ofpathologic situa-
tions. In several syndromes in which TNFa has been shown to play a role, comple-
ment activation also occurs. Endotoxemia in humans, meningococcal sepsis, and
malaria are examples, and in each situation, complement activation also has been
reported (21, 22).
Receptors forC5aare presenton neutrophilsandmonocytes, as well as othercells,
and its binding leads to cellular activation (5, 7). The occurrence of complement
activation with various shocksyndromessuch as septic andendotoxicshock, trauma,
and "shock lung," or the adult respiratory distress syndrome (ARDS), led to the hy-
pothesis that C5acaused activated neutrophils to adhere to and injure capillary en-
dothelial cells, leading to hypovolemia, shock, and ARDS (23). More recent evi-
dence calls into question the necessary participation of the "activated granulocyte"
in the pathogenesis ofthese syndromes, as they have been described in severely neu-
tropenic patients (24). With the demonstration of C5a as a potent stimulus to TNFa
and IL-1 secretion, C5a againemerges as apotentially important factor in thepatho-
genesis of this syndrome, independent of a requirement for neutrophil participa-
tion. It is thus possible that clinical syndromes as diverse as sepsis, trauma, cardio-
pulmonary bypass, or immune complex diseases, all associated with complement
activation, could result in fever, hypotension, coagulopathy, and disordered metabo-
lism. These effects of TNFa and IL-1 may in turn have resulted from the genera-
tion of C5a.
Summary
We have demonstrated that purified C5a is a potent stimulus to human PBMC
secretion o£ TNFa, IL-1p, and IL-1a, which proceeds in a dose-dependent fashion.
At a given concentration of C5a, TNFa andIL-1(3 secretion did notdiffer significantly;OKUSAWA ET AL.
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both were secreted in significantly greater quantity than IL-1a. Clinical conditions
such as Gram-positive and Gram-negative bacterial infections, trauma, and immune
complex diseases activate complement. Through the mediation ofTNF and IL-1 secreted
in response to C5a, these diverse disorders can share common features of fever,
coagulopathy, acute phase protein production, and disordered metabolism.
We thank Ms. Carol McClarey for the preparation of the manuscript.
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